H.R. 5811 · 115th Congress
Long-Term Opioid Efficacy Act of 2018
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Passed the House without a recorded vote, then expired. It passed by voice vote or unanimous consent, which don't record how each member voted, but didn't become law before the 115th Congress ended.
D
McNerneySponsor3 cosponsors · 3 R
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
- House Introduced May 15, 2018
- House Passed Jun 19, 2018
This bill expands the authority of the Food and Drug Administration (FDA)to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
What it does: CRS summary · Introduced in House · May 15, 2018
Long-Term Opioid Efficacy Act of 2018
This bill expands the authority of the Food and Drug Administration (FDA)to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Long-Term Opioid Efficacy Act of 2018
Latest action (Jun 20, 2018): Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: House · Introduced: May 15, 2018
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
- House Introduced May 15, 2018
- House Passed Jun 19, 2018
No recorded floor vote found.